OncLive® On Air cover image

S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML

OncLive® On Air

00:00

ASCEMBL Trial Design and Primary Endpoint

Elias Jabbour outlines the randomized phase 3 ASCEMBL trial comparing asciminib versus bosutinib in patients after ≥2 TKIs.

Play episode from 02:15
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app